ENTITY
Ascentage Pharma Group Corp

Ascentage Pharma Group Corp (6855 HK)

33
Analysis
Health CareChina
Ascentage Pharma Group International operates as a clinical-stage biotechnology company. The Company develops novel therapies for cancers, hepatitis B virus, age-related diseases, and more. Ascentage Pharma Group International conducts businesses in China, the United States, and other countries.
more
Refresh
16 Aug 2020 17:17

HSCI Index Rebalance - Stock Connect Flows Coming Up

The Hang Seng Indexes Company Limited (HSIL) announced the results of its review of the Hang Seng Family of Indexes post market close on 14 August....

Logo
472 Views
Share
22 Jul 2020 05:39

HSCI and Stock Connect - Biotech Stocks Now Eligible; Inclusion & Exclusion Possibilities

Hang Seng Indexes Company (HSIL) reviews the constituents of the Hang Seng Composite Index (HSCI) on a half yearly basis in March and September...

Logo
745 Views
Share
14 Apr 2020 13:47

Akesobio (康方生物) IPO: Expect near Zero Allocation

Akesobio launched book building to raise up to USD 333 million to list in Hong Kong. In our previous note, we discussed that the company features...

Logo
566 Views
Share
11 Mar 2020 14:39

InnoCare (诺诚健华) IPO: Momentum Matters but Mind the Limited Upside

InnoCare launched book building to raise up to USD 288 million to list in Hong Kong. In our previous notes, we have covered the company’s key...

Logo
403 Views
Share
04 Mar 2020 13:24

InnoCare (诺诚健华) Pre-IPO: PHIP and Valuation Update

InnoCare Pharma Limited is a clinical-stage biopharmaceutical company with a focus on small molecule inhibitors for BTK, and FGFRs. The company...

Logo
481 Views
Share
x